|
Every year, few novel drugs were approved by FDA, getting the chance to go public. Their treatment on different diseases interested the authors to find the reason why a certain drug can apply on the treatment from the initial state to the finished medicines and the efforts scientists took for the therapy of diseases. The Rukobia is a good option approved by FDA in 2020 as a novel HIV-1 treatment drug which can help the treatment for multi-drug resistance patients. With the rapidly increasing HIV patients, developing countries need to control and cure the patients with HIV and the treatment for those multi-drug resistance patients can effectively prolong their lives. Present drug therapy can’t satisfy the necessary of AIDS patients and the usual treatment cocktail therapy bring patients high drug resistance of first line drugs which means the patients will have no excellent alternative treatment after the cocktail therapy, finishing their lives with no hope. Although the HIV can be treated by the specific gene treatment but it can’t be applied on most of patients and the completely curative patients are only 4 until now, as a result, the drug treatment is still important for HIV therapy. Rukobia can’t cure the AIDS because the high replication rate of the HIV can’t be completely killed in the short time so the drug resistance will also produce after a period of treatment but the novel active site make it different from the known antiviral drugs. The authors want to explore the mechanism of Rukobia and the relationship between the drug development and treatment so Rukobia is a good option which applied the new standard and new methods so it has strong reference meaning for this review. In the future, scientists including the authors can apply the mentioned researching method the development and treatment of the new drugs for other diseases and the Rukobia treatment is summarized more clearly in this review.
|
